Direct Answer
190 SEC filers are classified under the Standard Industrial Classification code that describes the ophthalmology pharmaceuticals industry, and their latest annual reports show $454.1 billion of combined revenue and a median operating margin of -339.4%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.
Industry Overview
Ophthalmology pharmaceutical companies develop eye drops, injections and implants for dry eye, glaucoma and retinal disease. Intravitreal injections and chronic therapies create recurring revenue, with new formulations extending dosing intervals. The first numbers to compare across companies here are prescription or injection volume, net price and share in key categories.
Key Industry Metrics
- Prescription or injection volume: Number of prescriptions or injections. Chronic eye disease means repeat treatment, so volume growth follows patient starts and persistence.
- Net price: Price received after rebates and discounts. Competition and payer step therapy can reduce it even when list price is stable.
- Share in key categories: Portion of the market in categories such as retinal disease or dry eye. It shows competitive position as new mechanisms arrive.
- Pipeline and approvals: Candidates in trials and regulatory decisions. Longer-acting and new mechanism drugs can reset the competitive landscape.
- Patent timeline: Dates when protection ends and biosimilars or generics may enter. Timing shows how long current revenue is shielded.
Primary Macro Drivers
- Aging and diabetes prevalence: Retinal and glaucoma disease become more common with age and diabetes, which expands patients needing injections or drops.
- New mechanisms and longer-acting drugs: New drugs that last longer cut visits and improve adherence, which shift share and net price among key categories.
- Payer coverage and step therapy: Insurers often require cheaper drugs to be tried first, so coverage rules set how quickly new products are used.
- Biosimilar entry: Lower-priced copies of leading injections lower prices and take volume, which shapes pricing and share for original products.
Major Risks
- Biosimilars and generics: Copies of leading drugs lower prices and take volume; watch patent timeline and biosimilar launches in key categories.
- Safety events: Eye injections can cause inflammation or other serious events that lead to warnings or label limits; watch regulatory notices and safety data.
- Trial failures: A failed study stops a planned launch and its expected sales; watch pipeline stage and readout dates.
- Pricing pressure: Insurers and government programs push for lower prices and rebates, which lowers net price per injection; watch net price trends.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |
Ophthalmology Pharmaceuticals Filers in the SEC Record
190 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification code 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $454.1 billion of revenue. Median revenue growth over the prior year was 11.1%. Median operating margin was -339.4% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 40 of 190 reported a profit in their latest year.
| Company | Revenue | Growth | Operating margin | Net margin | Year |
|---|---|---|---|---|---|
| Johnson & Johnson | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 |
| Eli Lilly & Co | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 |
| Pfizer Inc | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 |
| Abbvie Inc. | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 |
| Bristol Myers Squibb Co | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 |
| Abbott Laboratories | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 |
| Viatris Inc | $14.3 billion | -3.0% | -18.6% | -24.6% | FY 2025 |
| Vertex Pharmaceuticals Inc / Ma | $12.0 billion | 8.9% | 34.8% | 32.9% | FY 2025 |
The 8 largest of 190 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.
Where to Go Next
The Ophthalmology Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Orthopedic Devices
- Ophthalmic Devices
- Patient Monitoring
- Oncology Pharmaceuticals
- Pharmaceuticals
- Oncology Biotechnology
- Pharmacy & Benefit Services
- Obesity & GLP-1 Therapeutics
Put it to work
Frequently Asked Questions
What are the main KPIs for the Ophthalmology Pharmaceuticals industry?
Key performance indicators for the Ophthalmology Pharmaceuticals industry include: Prescription or injection volume, Net price, Share in key categories, Pipeline and approvals, Patent timeline. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Ophthalmology Pharmaceuticals industry?
The Ophthalmology Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the Ophthalmology Pharmaceuticals industry?
The primary risks for Ophthalmology Pharmaceuticals companies include: Biosimilars and generics, Safety events, Trial failures, Pricing pressure. Investors should assess each company's exposure to these factors and its track record of navigating them.